← Back to Search

Selective Estrogen Receptor Modulator

Clomiphene Citrate for Low Testosterone

Phase 2
Recruiting
Led By Jonathan Gal, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male, 21-45 years of age
Serum testosterone concentration < 300 ng/dl measured on two separate occasions (separated by at least one week), with collection prior to 10AM
Must not have
History of pituitary tumor or resection of pituitary tumor
Documented allergy or hypersensitivity to clomiphene citrate or other SERM
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluation will occur at baseline, day 2, day 4, weeks 1 - 4, and again at weeks 8, 12, and 16.
Awards & highlights

Summary

This trial tests clomiphene citrate in men with low testosterone to see if it can naturally boost their hormone levels. The goal is to find a dose that doesn't require daily medication. Clomiphene citrate has been used to increase testosterone levels in men and improve reproductive health.

Who is the study for?
Men aged 21-45 with low testosterone (TT < 300 ng/dl) can join this trial. They must have had two tests a week apart showing low levels and be free from serious health issues like heart or liver disease, psychiatric disorders, bleeding problems, and certain hormonal conditions. No history of drug abuse or sensitivity to clomiphene is allowed.
What is being tested?
The trial is testing how the body processes two different doses of Clomiphene Citrate (25mg and 50mg) in men with low testosterone. Participants will be randomly assigned to receive one of the doses in an open-label setting where both they and the researchers know which dose is given.
What are the potential side effects?
Clomiphene Citrate may cause side effects such as vision changes, mood swings, pain in the testes, flushing, nausea, vomiting, headache. It's important for participants to report any discomforts they experience during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man aged between 21 and 45.
Select...
My testosterone levels are below 300 ng/dl, confirmed by two tests.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a pituitary tumor or surgery to remove one.
Select...
I am allergic to clomiphene or similar medications.
Select...
I have had testicular cancer or have undergone orchiectomy.
Select...
I have been diagnosed with primary hypogonadism.
Select...
I have had prostate cancer or severe prostate enlargement.
Select...
I have had chemotherapy, radiation to my groin/pelvis, or been exposed to agents harmful to reproductive organs.
Select...
I have had inflammation of the testicle or epididymis before.
Select...
I have a health condition like kidney, heart, liver disease, or others listed.
Select...
My tests show an abnormal chromosome structure.
Select...
I have been diagnosed with Kallmann syndrome.
Select...
I have had a urinary tract infection before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluation will occur at baseline, day 2, day 4, weeks 1 - 4, and again at weeks 8, 12, and 16.
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluation will occur at baseline, day 2, day 4, weeks 1 - 4, and again at weeks 8, 12, and 16. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in serum testosterone
Secondary study objectives
Change in FSH levels
Body Weight Changes
Change in estradiol levels

Trial Design

2Treatment groups
Experimental Treatment
Group I: Clomiphene citrate 50 mg every other day for 12 weeksExperimental Treatment1 Intervention
Group II: Clomiphene citrate 25 mg daily for 12 weeksExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clomiphene Citrate 50mg
2021
Completed Phase 4
~430
Clomiphene Citrate 25mg
2015
Completed Phase 2
~30

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for low testosterone include Clomiphene Citrate, testosterone replacement therapy (TRT), and aromatase inhibitors. Clomiphene Citrate, a Selective Estrogen Receptor Modulator (SERM), works by stimulating the release of gonadotropins (LH and FSH) from the pituitary gland, which in turn increases the production of testosterone by the testes. This is particularly important for patients with low testosterone as it helps restore natural testosterone production without directly introducing external testosterone, potentially preserving fertility. TRT involves the direct administration of testosterone, which can quickly alleviate symptoms but may suppress natural testosterone production and affect fertility. Aromatase inhibitors reduce the conversion of testosterone to estrogen, thereby increasing testosterone levels. Understanding these mechanisms helps patients and doctors choose the most appropriate treatment based on individual needs and long-term health goals.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,077 Previous Clinical Trials
1,320,627 Total Patients Enrolled
Jonathan Gal, MDPrincipal InvestigatorWeill Medical College of Cornell University
2 Previous Clinical Trials
170 Total Patients Enrolled
Caroline Kang, MDPrincipal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
70 Total Patients Enrolled

Media Library

Clomiphene Citrate (Selective Estrogen Receptor Modulator) Clinical Trial Eligibility Overview. Trial Name: NCT05096169 — Phase 2
Low Testosterone Research Study Groups: Clomiphene citrate 25 mg daily for 12 weeks, Clomiphene citrate 50 mg every other day for 12 weeks
Low Testosterone Clinical Trial 2023: Clomiphene Citrate Highlights & Side Effects. Trial Name: NCT05096169 — Phase 2
Clomiphene Citrate (Selective Estrogen Receptor Modulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05096169 — Phase 2
~4 spots leftby Jan 2025